Author: Ravi Shankar

— Clearance highlights continued execution, modularity and momentum across Prime Medicine’s liver franchise, building on recent regulatory clearances for PM577a —

— Initial clinical data expected in 2027 —

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for PM647, an investigational in vivo Prime Editor for Alpha-1 Antitrypsin Deficiency (AATD). The clearance enables PM647 to proceed to clinical study initially in the United States, where approximately 100,000 people carry the PiZZ genotype that PM647 is designed to correct.

“FDA clearance of the PM647 IND is an important milestone for Prime Medicine, marking continued momentum across our liver franchise,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “PM647 has the potential to change how AATD is treated, offering a Prime Editing-based approach that moves beyond protein replacement and targets the root cause of disease. By correcting the underlying mutation and restoring production of fully functional AAT, PM647 may simultaneously address both lung and liver manifestations of AATD and provide a differentiated, one-time treatment approach for patients. Beyond its therapeutic potential, PM647 demonstrates the repeatability and productivity of Prime Medicine’s platform. Just months after regulatory clearances for PM577a, the advancement of PM647 into clinical development also reinforces how Prime Medicine’s modular platform and universal liver LNP can support the rapid progression of multiple programs.”

Phase 1/2 Clinical Trial

The Phase 1/2 clinical trial will be a global, single-arm, open-label, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of a one-time intravenous infusion of PM647 in adults with AATD. The study will initially enroll adult participants with lung-only manifestations of AATD. Upon demonstration of tolerability in lung-only participants, the study will expand to include a separate cohort enrolling adults with significant liver disease, with or without concurrent lung manifestations of AATD.

About PM647

PM647 is an investigational, one-time in vivo Prime Editor designed to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, the most common cause of AATD. By correcting the mutation at its source, PM647 is designed to restore production of functional M-AAT and address both the liver and lung manifestations of the disease. In fully humanized mouse models, PM647 achieved high editing efficiency and restored corrected M-AAT protein into the healthy human range at clinically relevant doses with a single infusion. PM647 uses the same liver-directed lipid nanoparticle (LNP) as PM577a, Prime Medicine’s investigational program for Wilson disease.

About Alpha-1 Antitrypsin Deficiency

Alpha-1 Antitrypsin Deficiency is an inherited genetic disorder caused by variants in the SERPINA1 gene. In people with severe disease, insufficient functional alpha-1 antitrypsin can lead to progressive lung damage, while accumulation of mutant protein in the liver can cause progressive liver disease. Patients have no approved curative treatment that addresses the underlying genetic cause of both manifestations of the disease. Approximately 200,000 people are estimated to carry the PiZZ genotype across United States and Europe.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the potential of PM647 to correct the causative mutations of, and to treat, AATD; the Phase 1/2 clinical trial of PM647, including the trial design, global reach of the trial and the anticipated timing of initial clinical data in 2027; the continued development and advancement of the Company’s AATD and Wilson disease programs; the modularity of the Prime Editing platform and universal liver LNP and the benefits thereof; and the potential of Prime Editing to unlock opportunities across thousands of potential indications.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

Long-term roadmap integrates music, education, wellness, hospitality, and residential real estate into a single destination ecosystem on Chiba’s Pacific coast

CHOSHI, CHIBA PREFECTURE, JAPAN, Sept. 24, 2026 (GLOBE NEWSWIRE) — OFA Group today outlined its long-term development vision and roadmap for a new oceanfront cultural destination in Choshi City, a multi-phase initiative designed to bring together classical music and the arts, education, wellness, hospitality, and residential real estate into one cohesive destination ecosystem on Japan’s Pacific coast.

Located at the easternmost tip of the Kanto region, Choshi is known for its rugged coastline, the historic Inubosaki Lighthouse, some of the first sunrises in mainland Japan, a working fishing port, and the local Choshi Dentetsu rail line. OFA sees the city’s natural setting and cultural heritage as the foundation for a destination that draws visitors, residents, and cultural institutions together in one place, rather than developing music, housing, and hospitality as separate, disconnected efforts.

“This is about more than any single building or event,” said Larry Wong, CEO of OFA Group. “We are working to organically link music, education, wellness, hospitality, and residential living so that Choshi’s identity as a cultural destination and OFA’s long-term investment in the city grow together, not on separate tracks. Every piece of this roadmap is designed to reinforce the others.”

Music as the cultural core. At the center of OFA’s roadmap is a renewed commitment to classical music as Choshi’s defining cultural asset. Building on lessons from its earlier festival programming, OFA is re-establishing its approach around a sustainable, brand-led business model — one that will inform how future concerts, education programs, and performance venues are developed, rather than starting from venues and working backward. OFA is in early discussions with cultural producers and organizers about multi-year programming that could begin as soon as 2028, and will share further details as those conversations progress.

A coastal home for wellness and residential living. As part of the same vision, OFA is pursuing the redevelopment of a coastal parcel in Choshi’s Tokawa area into a premium, private-pay senior living community — a short walk from Choshi Dentetsu’s Tokawa Station and the coastline. The project, currently under a provisional agreement with Choshi City and subject to City Council approval, is envisioned as a residence where wellness, hospitality-grade service, and Choshi’s emerging cultural identity come together for residents, rather than a standalone care facility. Planning work, including site design and regulatory review, is underway.

Education and hospitality as connective tissue. OFA’s roadmap also calls for education programming — tied to the destination’s music and cultural offerings — and hospitality experiences that welcome visitors to Choshi for the first time and give residents and program participants reasons to stay engaged over the long term. These components are earlier in development and will be shaped in coordination with the music and residential pillars as they mature.

OFA intends to advance this roadmap in phases over the coming years, working closely with Choshi City, local stakeholders, and prospective partners at each stage. The company will provide updates as key milestones — including municipal approvals, program partnerships, and site plans — are finalized.

About OFA Group

​​OFA Group (NASDAQ: OFAL) is a technology-driven architecture, real estate, and digital asset infrastructure company operating at the intersection of AI, construction, and blockchain. OFA is revolutionizing the architectural industry by integrating cutting-edge AI technology and an interdisciplinary approach, which improves processes for building code compliance, construction design, time management, labor efficiency, effectiveness, and overall productivity. Learn more at OFAgroup.com. 

Forward-Looking Statements 

This press release contains forward-looking statements. These forward-looking statements are not historical facts, but only predictions and generally can be identified by use of statements that include phrases such as “will,” “may,” “should,” “continue,” “anticipate,” “assume,” “believe,” “expect,” “plan,” “appear,” “project,” “estimate,” “hope,” “intend,” “target,” “forecast,” or other words or phrases of similar import. Similarly, statements that describe our objectives, plans or goals also are forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those currently anticipated. These forward-looking statements include, but are not limited to, statements regarding the expected capabilities, adoption, commercialization, market acceptance, future development, revenue opportunities, customer growth, product enhancements, and business strategy relating to the QikBIM platform. Actual results may differ materially due to various risks and uncertainties, including market acceptance of the Company’s AI technologies, customer adoption rates, competitive developments, technological challenges, regulatory changes, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release are made only as of the date of this press release. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law. 

Media Contact 
Susan Fortner 
President, BPR International 
Susan@BPRInternational
614.562.0054 

Investor Relations
OFA Group
Email: info@ofagroup.com
Website: www.ofagroup.com

CHICAGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Amlan^® International, the animal health business of Oil-Dri^® Corporation of America, will return to World Dairy Expo as the official Media Room sponsor. Taking place September 29–October 2 in Madison, Wisconsin, World Dairy Expo brings together dairy producers, industry professionals and media from around the world to exchange insights and explore the latest developments shaping the global dairy industry.

This year marks Amlan’s fifth consecutive year sponsoring the Media Room, reflecting the company’s continued commitment to supporting the dairy industry and advancing conversations around feed safety, animal health and productivity.

During the show, Dr. Wade Robey, President, Amlan International, will be available for media interviews to discuss evolving mycotoxin challenges facing dairy producers. In particular, Dr. Robey will share insights into rising levels of zearalenone and the potential implications for herd fertility, as well as why producers should consider the broader impact of exposure to multiple mycotoxins.

“Today’s mycotoxin challenges extend well beyond any single toxin,” said Dr. Robey. “As toxin prevalence continues to evolve, producers need to understand what may be present in their feed and how those challenges can affect herd health, reproductive performance and overall productivity.”

As part of its Media Room sponsorship, Amlan invites registered media attending World Dairy Expo to enjoy a complimentary boxed lunch on Tuesday, September 29, from 11 a.m. to 1 p.m.

“Amlan values the opportunity World Dairy Expo provides to connect with the people who are helping move the dairy industry forward,” said Reagan Culbertson, Vice President, Strategic Marketing, B2B. “Supporting the Media Room is one way we can help encourage the exchange of information and ideas while continuing important conversations around the challenges and opportunities facing dairy producers.”

Media interested in scheduling an interview with Dr. Robey during World Dairy Expo are encouraged to contact Lily Nemeroff, Marketing and Communications Manager, at lily.nemeroff@amlan.com.

For more information about Amlan International, visit www.amlan.com.

Company Information
Amlan is the animal health business of Oil-Dri Corporation of America, a leading global manufacturer and marketer of sorbent minerals. Leveraging over 80 years of expertise in mineral science, Oil-Dri Corporation of America, doing business as “Amlan International,” is a publicly traded company on the New York Stock Exchange (NYSE: ODC). Amlan International sells feed additives worldwide. Product availability may vary by country; associated claims do not constitute medical claims and may differ based on government requirements.

Contact:
Reagan Culbertson, Vice President of Strategic Marketing, B2B
Reagan.culbertson@amlan.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c1313a99-b364-4f65-a67e-3ee701e0b88f

New York, NY, Sept. 24, 2026 (GLOBE NEWSWIRE) — Live Oak Acquisition Corp. VI (the “Company”) announced today the closing of its initial public offering of 23,000,000 units, which includes 3,000,000 units issued pursuant to the exercise by the underwriters of their over-allotment option in full. The offering was priced at $10.00 per unit, resulting in gross proceeds of $230,000,000. The Company’s units began trading on September 23, 2026 on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “LOVIU” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment. Only whole warrants are exercisable. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The warrants will become exercisable 30 days after the completion of the Company’s initial business combination, and will expire five years after the completion of the Company’s initial business combination or earlier upon redemption or its liquidation. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “LOVI” and “LOVIW,” respectively.

Of the proceeds received from the consummation of the initial public offering and a simultaneous private placement of warrants, $230,000,000 (or $10.00 per unit sold in the offering) was placed in a trust account of the Company.

The Company is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any business or industry. The Company’s management team is led by Richard Hendrix, its Chairman, Chief Executive Officer and the co-founder of Live Oak Merchant Partners (“Live Oak”), and Adam Fishman, its President, Chief Financial Officer, Director and a Managing Partner of Live Oak. The Board also includes Ashton Hudson, Andrea Tarbox and Somsak Chivavibul. Gary Wunderlich, Jr. serves as a Senior Advisor.

Santander acted as the sole underwriter for the offering.                                    

The offering was made by means of a prospectus. Copies of the prospectus may be obtained from Santander US Capital Markets LLC, 437 Madison Avenue, New York, NY 10022, Attention: ECM Syndicate, by email at equity-syndicate@santander.us, or by telephone at 833-818-1602. A registration statement relating to the securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 22, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all.

Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contacts

Live Oak Acquisition Corp. VI
4921 William Arnold Road
Memphis, Tennessee 38117
Attn: Adam Fishman
E-mail: IR@liveoakmp.com 

Proceeds to Expand SOL Holdings and Accelerate SOL Per Share Growth

AUSTIN, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) — Forward Industries, Inc. (NASDAQ: FWDI) (the “Company” or “Forward”), the leading Solana treasury company, today announced the closing of its previously announced registered direct offering with an institutional investor. The Company sold 3,125,000 shares of its common stock at a price of $8.00 per share. Forward received gross proceeds of approximately $25 million, before deducting placement agent fees and other offering expenses, and intends to use the net proceeds primarily to acquire additional SOL.

“Forward is growing rapidly, and we are strengthening our financial position as we scale. We secured substantial institutional capital in a single transaction on terms we believe are favorable, without adding ongoing balance sheet obligations. This financing positions us to expand our SOL treasury and increase SOL per share—the measure of growth that matters most to our shareholders. We now have additional capital to extend our competitive lead and pursue opportunities from a position of strength. Our progress reflects disciplined capital allocation and a clear focus on translating treasury growth into lasting shareholder value,” said Ryan Navi, Chief Investment Officer of Forward.

The shares were offered pursuant to the Company’s shelf registration statement on Form S-3ASR (File No. 333-290312), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 16, 2025. A prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying prospectus may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.

A.G.P./Alliance Global Partners acted as sole placement agent for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Forward Industries, Inc.

Forward Industries, Inc. (NASDAQ: FWDI) is a Solana focused digital asset treasury company, with the strategy to buy, hold, stake, trade, invest in, and grow SOL and SOL related digital assets, protocols and businesses. Forward’s mission is to expand and strengthen the Solana ecosystem by acquiring and staking SOL and engaging with, providing tools to and investing in the Solana network, Solana developers and Solana related projects in order to increase shareholder value. In connection with a private placement transaction in September 2025, Forward launched a digital asset treasury strategy supported by industry leading investors and operating partners including Galaxy Digital and Jump Crypto. For more information on the Company’s Solana treasury strategy, visit www.forwardindustries.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters including statements relating to the anticipated use of proceeds from the offering, the expected impact of the offering on SOL per share, the Company’s plan for value creation and strategic advantages, and market size and growth opportunities. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: failure to realize the anticipated benefits of the digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price of Solana and other cryptocurrencies and the incurrence of indebtedness; the risk that the price of the Company’s common stock may be highly correlated to the price of the digital assets that it holds; risks related to the performance and expected return of the companies and projects that the Company has invested in; risks related to increased competition in the industries and markets in which the Company does and will operate (including the applicable digital assets market); risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; as well as those risks and uncertainties identified in the Company’s filings with the SEC. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements. Investors should not place undue reliance on forward-looking statements.

Contacts
Media Contact
comms@forwardindustries.com

Investor Relations Contact
Sean Mansouri, CFA / Aaron D’Souza
Elevate IR
(720) 330-2829
ir@forwardindustries.com

Resort-style amenities enhance vibrant new home community

VENICE, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the expansive Wellen Park amenity center is now open for residents of its Oakbend Wellen Park community in Venice, Florida. Oakbend Wellen Park is a gated community of new luxury homes by Toll Brothers, and the highly anticipated debut of the exclusive amenities in the Wellen Park master plan marks an exciting milestone for current and future residents.

The newly completed amenity center features a resort-style pool, state-of-the-art fitness center, clubhouse with social lounge, pickleball and bocce courts, a playground, a viewing dock, and walking and biking trails. These thoughtfully curated amenities provide the opportunity for residents to enjoy an active and vibrant lifestyle.

“The highly anticipated opening of this incredible amenity center is an exciting development for our Oakbend Wellen Park community, offering residents a host of resort-style amenities designed to foster relaxation, recreation, and connection,” said Brian O’Hara, Division President of Toll Brothers in Tampa-Sarasota. “This community’s unique blend of luxury homes and premier amenities makes it the perfect choice for home shoppers seeking a relaxed yet elevated lifestyle in the Venice area.”

Oakbend Wellen Park offers one- and two-story single-family home designs ranging from approximately 1,872 to over 3,100 square feet with 3 to 6 bedrooms, 2.5 to 5.5 baths, and 2- to 3-car garages. Homes feature spacious floor plans with options for lofts, flex rooms, and stunning outdoor living spaces. Pricing starts from the upper $400,000s.

Toll Brothers customers will experience one-stop shopping at the Toll Brothers Design Studio. The state-of-the-art Design Studio allows home shoppers to choose from a wide array of selections to personalize their dream home with the assistance of Toll Brothers professional Design Consultants.

Located in the top-rated Sarasota County School District, Oakbend Wellen Park is ideally situated near Florida’s beautiful beaches and offers convenient access to the Downtown Wellen District and CoolToday Park. Residents can enjoy waterfront shopping, dining, and entertainment just minutes from their doorstep.

For more information on Oakbend Wellen Park and Toll Brothers communities throughout Florida, call 855-600-8655 or visit TollBrothers.com/FL.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/83daf748-ad12-4eb6-aa93-caeffd5d294e

https://www.globenewswire.com/NewsRoom/AttachmentNg/8687fe62-483f-4e5f-8704-326b6b840620

https://www.globenewswire.com/NewsRoom/AttachmentNg/e6c5cb4f-358c-4a86-8312-2c681458b88f

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

New luxury community will offer townhomes and single-family homes within the vibrant Cumming City Center district

CUMMING, Ga., Sept. 24, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced Cloverhill at Cumming City Center is coming soon to one of North Georgia’s most sought-after locations, bringing a new collection of luxury townhomes and single-family homes to the heart of Cumming. This new community will feature thoughtfully designed new construction homes within walking distance of Cumming City Center, offering residents an unparalleled blend of convenience, connectivity, and modern living. Site work is underway at 519 Canton Rd in Cumming, and the community is expected to open for sale in spring 2027.

Located near highly regarded Forsyth County schools and just minutes from Highway 20 and GA-400, Cloverhill at Cumming City Center places homeowners close to the area’s premier shopping, dining, recreation, and employment destinations while maintaining a strong sense of neighborhood and community.

The new community will offer three distinctive home collections designed to accommodate a variety of lifestyles and life stages:

• The Alder Collection – Luxury 1,900+ square foot townhomes with sophisticated designs and modern conveniences
• The Juniper Collection – Stylish 2,633+ square foot townhomes featuring versatile layouts and contemporary finishes
• The Wildflower Collection – Spacious 2,319+ square foot detached single-family homes with elevated architecture and flexible living spaces

Prospective homebuyers will have the opportunity to tour two professionally decorated model homes when the community opens this spring, showcasing the exceptional craftsmanship, contemporary interiors, and personalization opportunities available throughout the neighborhood.

“At Cloverhill at Cumming City Center, homeowners will experience a lifestyle where luxury, comfort, and connection come together,” said Eric White, Division President of Toll Brothers in Georgia. “From thoughtfully designed homes and resort-inspired amenities to the walkable access to Cumming City Center’s vibrant mix of shopping, dining, entertainment, and outdoor gathering spaces, this community offers a truly unique opportunity to enjoy the best of Georgia living.”

Residents will enjoy access to a robust amenity package designed to encourage recreation, wellness, and social connection, including a clubhouse, resort-style swimming pool, fitness center, tennis courts, playground, and community gathering spaces.

Beyond the neighborhood, residents will benefit from the energy and excitement of Cumming City Center, where shopping, dining, year-round events, scenic outdoor spaces, and social activities are just steps from home. The community’s premier location also provides convenient access to popular North Georgia destinations, including Lake Lanier and Sawnee Mountain Preserve.

“With its combination of luxury home designs, exceptional amenities, highly regarded schools, and an unbeatable location, Cloverhill at Cumming City Center is poised to become one of Cumming’s most desirable new home communities,” added White.

For more information, contact Toll Brothers at 888-686-5542 or visit TollBrothers.com/GA.

About Toll Brothers
Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses. 

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com. 

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | ameck@tollbrothers.com

Photos accompanying this announcement are available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/843a1d62-195b-4fa1-b54a-c8046bb16ce7

 https://www.globenewswire.com/NewsRoom/AttachmentNg/4ce35da9-c446-46a2-a893-c1882f4f5207

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

Company Announcement

COPENHAGEN, Denmark; September 24, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 13,794 restricted stock units and 13,331 warrants to employees of the Company and the Company’s subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,268.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. 

The exercise price for each warrant is DKK 2,268. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 781.96.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the Board of Directors on February 23, 2021. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Governance > Compensation > Warrants.

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 38
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 240926_CA38_Warrant and RSU grant

HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) — KOIL Energy Solutions Inc. (OTCQB: KLNG), a leading provider of subsea equipment and services to the global energy and offshore industries, today announced that members of its executive leadership team will participate in the following investor conferences during October 2026.

National Investment Banking Association 153rd Investment Conference
Conference Dates: Oct. 6-7, 2026
Presentation Date: Wednesday, Oct. 7, 2026
Location: The Westin Fort Lauderdale Beach Resort, Fort Lauderdale, Florida
Presenter: Kurt Keller, Chief Financial Officer

Mr. Keller will present and participate in investor meetings at the National Investment Banking Association’s 153rd Investment Conference.

The ThinkEquity Conference 2026
Conference Date: Thursday, Oct. 15, 2026
Presentation Date: Thursday, Oct. 15, 2026
Location: New York, New York
Presenters: Erik Wiik, President and Chief Executive Officer, and Kurt Keller, Chief Financial Officer

Mr. Wiik and Mr. Keller will present and participate in investor meetings at the ThinkEquity Conference, which includes a dedicated Oil & Gas track.

Planet MicroCap Showcase: Toronto 2026
Conference Dates: Oct. 27-29, 2026
Presentation Date: Wednesday, Oct. 28, 2026, at 2:30 p.m. Eastern time
Location: Arcadian Loft, Toronto, Canada
Presenter: Erik Wiik, President and Chief Executive Officer

Mr. Wiik will present and participate in investor meetings at Planet MicroCap Showcase: Toronto 2026.

Management expects to discuss KOIL’s ongoing execution of its KOIL 2030 strategy, including the company’s focus on integrated systems solutions, expansion in Brazil, and continued investment in rental equipment and services.

Investors interested in arranging meetings with KOIL management during these events should contact the respective conference organizers or KOIL Investor Relations at ir@koilenergy.com.

About KOIL (www.koilenergy.com)

KOIL Energy is a leading energy services company offering subsea equipment and support services to the world’s energy and offshore industries. We provide innovative solutions to complex customer challenges presented between the production facility and the energy source. Our core services and technological solutions include distribution system installation support and engineering services, umbilical terminations, loose-tube steel flying leads, and related services. Additionally, KOIL Energy’s experienced team can support subsea engineering, manufacturing, installation, commissioning, and maintenance projects located anywhere in the world.

Forward-Looking Statements

Any forward-looking statements in the preceding paragraphs of this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties in that actual results may differ materially from those projected in the forward-looking statements. In the course of operations, we are subject to certain risk factors, competition and competitive pressures, sensitivity to general economic and industrial conditions, international political and economic risks, availability and price of raw materials and execution of business strategy. For further information, please refer to the Company’s filings with the Securities and Exchange Commission, copies of which are available from the Company without charge.

Investor Relations Contact:

ir@koilenergy.com

281-862-2201

Cergy, September 24, 2026 – SPIE (the “Company”), the independent European leader in multi-technical services in the areas of energy and communications, today announces the results of the repurchase of a part of its sustainability-linked bonds settled in cash and/or convertible into new shares and/or exchangeable for existing shares due January 2028 (FR001400F2K3) (the “2028 ORNANEs”) announced on September 22, 2026 (the “Repurchase”).

The Company collected, via a reverse bookbuilding process conducted on September 22, 2026, indications of interest from holders of the outstanding 2028 ORNANEs.

Following the close of this reverse bookbuilding process carried out by BNP PARIBAS and Natixis as Joint Dealer Managers, SPIE has decided to accept the repurchase of 2,801 2028 ORNANEs in a principal amount of 280.1 million euros, representing approximately 70% of the number of the 2028 ORNANEs initially issued.

The final repurchase price pursuant to this process was set at 138,487 euros per 2028 ORNANE representing a total consideration of approximately 388 million euros. This final repurchase price was determined by reference to the initial repurchase price of 135,000 euros per 2028 ORNANE, determined at the close of the reverse bookbuilding process, adjusted for the change in price of a share of SPIE during the period starting on (and including) September 22, 2026 and ending on (and including) September 24, 2026, i.e., a reference share price of 44.1118 euros¹. In addition, the Company will pay interest accrued on the 2028 ORNANEs up to (but excluding) the settlement date of the Repurchase.

The settlement of the Repurchase is expected to take place on October 1, 2026 and is conditional upon the settlement of the issue of the new 500 million euros sustainability-linked notes due 2032 which is expected to occur on September 28, 2026.

The 2028 ORNANEs accepted in the Repurchase will be cancelled in accordance with their terms and conditions (the “Terms and Conditions”).

As announced in its press release published on September 22, 2026, it is reminded that SPIE will proceed with the early redemption of all remaining outstanding 2028 ORNANEs following the Repurchase, i.e., 1,073 2028 ORNANEs, in accordance with the 2028 ORNANEs Terms and Conditions.

The date of early redemption of the 2028 ORNANEs will be October 22, 2026 (the “Early Redemption Date”).

Pursuant to section 10.3.1 of the Terms and Conditions, the 2028 ORNANEs will be redeemed at par plus interest accrued, i.e., 100,527.17 euros per 2028 ORNANEs.

Pursuant to section 10.3.3 of the Terms and Conditions, the holders of 2028 ORNANEs retain the ability to request the exercise of their conversion/exchange right in accordance with the Terms and Conditions until the seventh trading day (included) preceding the Early Redemption Date, i.e. until October 13, 2026 (included). 

The Company reiterates its intention to deliver new and/or existing shares only in the event that holders of the remaining outstanding 2028 ORNANEs following the Repurchase exercise their conversion and/or exchange rights.

It is further recalled that, in accordance with the Terms and Conditions, the Company’s decision to deliver new and/or existing shares (i.e., the Decision Date as defined in the Terms and Conditions) will occur 3 trading days after each conversion and/or exchange request made by a holder of 2028 ORNANEs on any Exercise Request Date (as defined in the Terms and Conditions).

Any holder of 2028 ORNANEs that will not have requested the exercise of his or her conversion/exchange right in accordance with the Terms and Conditions prior to this date will be redeemed in the conditions set out above.

This press release does not contain and does not constitute an offer to sell securities, nor an invitation or solicitation to invest in securities in France, the United States, or any other jurisdiction.

About SPIE

SPIE is the independent European leader in multi-technical services in the areas of energy and communications. With 55,000 employees, SPIE works alongside its customers to drive the energy, digital and industrial transitions. As a key player in decarbonisation, the Group delivers efficient and innovative solutions across the economy.

SPIE Group achieved in 2025 consolidated revenue of €10.4 billion and consolidated EBITA of €793 million.

www.spie.com
Facebook –LinkedIn
Press Media Library

Contacts

SPIE Pascal Omnès Group Communications Director Tel. + 33 (0)1 34 41 81 11 pascal.omnes@spie.com

SPIE Investor Relations Investors@spie.com

IMAGE 7 Laurent Poinsot Tel. + 33 (0)1 53 70 74 70 spie@image7.fr

Disclaimer

This announcement does not constitute an invitation to participate in the Repurchase in or from any jurisdiction in or from which, or to or from any person to or from whom, it is unlawful to make such invitation under applicable securities laws. The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions. Tenders of 2028 ORNANEs for purchase in the Repurchase will not be accepted from qualifying holders in any circumstances in which such offer or solicitation is unlawful.

The Company does not make any recommendation as to whether or not qualifying holders should participate in the Repurchase. If any holder of the 2028 ORNANEs is in any doubt as to the contents of the Repurchase, or the action it should take, it is recommended to seek its own financial advice, including in respect of any tax consequences, from its broker, bank manager, solicitor, accountant or other independent financial, tax or legal adviser.

---

¹ Corresponding to the arithmetic average of the value-weighted average price of SPIE shares over three consecutive trading days (from September 22, 2026 to September 24, 2026 included).

Attachment

• SPIE announces the results of the repurchase of its ORNANEs due January 2028 for approximately 388 million euros